Search - tctmd.com

Displaying 141 - 160 of 264

Sort: Relevancy | Date

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

Caitlin E. Cox

March 31, 2022

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News THT 2022

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

L.A. McKeown

February 03, 2022

News Conference News STS 2022

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

L.A. McKeown

February 02, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Daily News

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

Shelley Wood

November 01, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

Todd Neale

September 20, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

Advertisement

April 2022 News Roundup

A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

March 2022 News Roundup

TCTMD’s Top 10 Most Popular Stories for February 2022

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

PA Pressure Monitoring Useful Even in Presymptomatic CHF Patients

Bicuspid SAVR Outcomes Meet or Beat Tricuspid in STS Database

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Canagliflozin Improves Quality of Life in HF Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content